

## MiR-206 decreases brain-derived neurotrophic factor levels in a transgenic mouse model of Alzheimer's disease

Ning Tian<sup>1</sup>, Zeyuan Cao<sup>3</sup>, Yan Zhang<sup>2</sup>

<sup>1</sup>Beijing Obstetrics & Gynecology Hospital, Capital Medical University, Beijing 100026, China

<sup>2</sup>State Key Laboratory of Biomembrane and Membrane Biotechnology, College of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing 100871, China

<sup>3</sup>The High School affiliated to Renmin University of China, Beijing 100080, China

Corresponding author: Yan Zhang. E-mail: [yanzhang@pku.edu.cn](mailto:yanzhang@pku.edu.cn)

© Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2014

### ABSTRACT

MicroRNA alterations have been reported in patients with Alzheimer's disease (AD) and AD mouse models. We now report that miR-206 is upregulated in the hippocampal tissue, cerebrospinal fluid, and plasma of embryonic APP/PS1 transgenic mice. The increased miR-206 downregulates the expression of brain-derived neurotrophic factor (BDNF). BDNF is neuroprotective against cell death after various insults, but in embryonic and newborn APP/PS1 mice it is decreased. Thus, a specific microRNA alteration may contribute to AD pathology by downregulating BDNF.

**Keywords:** miR-206; brain-derived neurotrophic factor; APP/PS1; cell death; Alzheimer's disease

### INTRODUCTION

Alzheimer's disease (AD) is the most common cause of dementia in the population >65 years old<sup>[1]</sup>. It is associated with impairments in memory, language, behavior, and cognition<sup>[1]</sup>. The brain of AD patients is characterized by the presence of senile plaques and neurofibrillary tangles together with synaptic and neuronal cell loss<sup>[1]</sup>. Many microRNAs (miRNAs) have been implicated in AD<sup>[2–4]</sup>. miRNAs are a group of short (~21–23 nucleotides) non-coding RNAs<sup>[5]</sup> with conserved roles in *Drosophila*, rodents, monkeys, and humans<sup>[6–9]</sup>. miRNA precursors are first processed into single-stranded miRNAs that bind to the 3' untranslated region (UTR)

of the complementary target mRNA sequences<sup>[10]</sup>, leading to translational repression or target degradation<sup>[11, 12]</sup>. A specific miRNA can have several hundred target gene sequences and regulate many pathways<sup>[13, 14]</sup>.

Neurotrophins have been reported to play important roles in the physiopathology of AD<sup>[15]</sup>. Brain-derived neurotrophic factor (BDNF) is the most widely expressed neurotrophin in the central nervous system<sup>[16]</sup>, and plays critical roles in neurite outgrowth, directional guidance, the induction of long-term potentiation, and neurotransmitter release<sup>[17]</sup>. It also regulates gene transcription, such as nuclear factor kappa B and c-Jun N-terminal kinase-p53-Bax, and activates intracellular signaling pathways, including Ras/mitogen-activated protein kinase, phosphatidylinositol 3/Akt, and phospholipase C pathways<sup>[18]</sup>. Moreover, BDNF has been associated with AD pathology. In cultured neurons, BDNF protects against amyloid  $\beta$  ( $A\beta$ )<sub>1–42</sub> toxicity<sup>[19]</sup>. It also rescues the damage induced by amyloid in rodent and primate models of AD<sup>[20]</sup>. On the other hand,  $A\beta$ <sub>1–42</sub> decreases BDNF expression in cortical neurons and affects its intracellular trafficking<sup>[21]</sup>. In AD transgenic mouse models, BDNF is negatively correlated with the cerebral amyloid burden<sup>[22]</sup>. In addition, genetic association studies have linked BDNF polymorphisms to an increased risk of AD in humans<sup>[23–26]</sup>. Taken together, BDNF is implicated in AD pathogenesis.

In the present study, we set out to determine the mechanism of how BDNF is altered and whether some miRNA regulation is involved in such alteration.

## MATERIALS AND METHODS

### Cell Culture

Primary neurons were cultured from embryonic day 14 (E14) APP/PS1 (APP<sup>swe</sup>/PS1 $\Delta$ E9) mouse hippocampus, following the regulations of Peking University Animal Care and Use Committee as previously described<sup>[27]</sup>. SH-Sy5y cells were cultured with minimum essential medium (Invitrogen, Carlsbad, CA).

### Reagents and Sequences of miRNAs and 3'UTR and Real-time PCR

Mouse miR-206, scrambled microRNA control (5'-GTGTAACACGTCTATACGCCCA-3'), mimic miR-206 (5'-UGGAAUGUAAGGAAGUGUGUGG-3'), an miR-206 inhibitor (5'-ACAUGCUUCUUUAUCCUCAUA-3'), mutant miR-206 (5'-UGGAAUGUAAGG**CC**GUGUGUGG-3'), and complementary sequence (5'-ACATTCC-3') were all purchased from Qiagen (Hilden, Germany). The altered mouse BDNF mRNA 3'UTR sequences used were as follows: mutant BDNF mRNA 3'UTR: 5'-ACAAACC-3' and MAP2 3'UTR: 5'-CATATTCATTCTTACAAACCATAG-3'. All WT and modified 3'UTR sequences were cloned into a pLenti-Luc-UTR or pLenti-EGFP-UTR vector backbone (Abm, Richmond, Canada). miRNAs were transfected into SH-Sy5y cells with HiPerFect transfection agent (Qiagen). BDNF (Sigma, St. Louis, MO), A $\beta$ <sub>1-42</sub> (Bachem, Torrance, CA), staurosporine (STS, Sigma), etoposide (Etop, Sigma) and glutamate (Sigma) were stored in 100 $\times$  stock solution and diluted with culture medium before use. Real-time PCR was done following the described procedure<sup>[28]</sup>. miR-206 levels in tissue, serum, and cerebrospinal fluid (CSF) were measured by the TaqMan MicroRNA assay kit for Mmu-miR-206 according to the manufacturer's instructions (Life Technologies Corp., Carlsbad, CA).

### Western Blots and Measurement of Neuronal Cell Death

Western blots were performed following the protocols described previously<sup>[27]</sup>. Anti-BDNF (Abcam, Cambridge, UK) and actin (Sigma) antibodies were diluted at 1:1 000 for Western blots as primary antibodies. The relative density was calculated as the total absolute density of BDNF/actin control. Secreted BDNF was calculated by equal loading of the same volume of culture medium. Cell death was

measured by terminal deoxynucleotidyl transferase-biotin dUTP nick-end labeling (TUNEL) using *in situ* cell death detection kit I according to the manufacturer's description (Roche, Quebec, Canada)<sup>[27]</sup>.

### Luciferase Reporter Assays

The effect of miR-206 on BDNF expression was investigated using the Dual-Luciferase Reporter Assay System kit (E1910; Promega, Madison, WI). The constructs with the firefly (*Photinus pyralis*) luciferase gene downstream of the BDNF 3'UTR were co-transfected with WT, mutant, scrambled, or mimic miR-206, or with miR-206 inhibitor, into SH-Sy5y cells. Firefly luminescence was detected as indicated by the manufacturer. For the control of transfection efficiency, *Renilla* (*R. reniformis*) luciferase construct was co-transfected into the cells. The activity was corrected as (firefly/*Renilla* luciferase)  $\times$ 10 000. The luminescence was expressed as relative light units<sup>[29]</sup>.

### Enzyme-linked Immunosorbent Assay (ELISA)

ELISA kits were used to determine the concentrations of BDNF (R&D Systems, Minneapolis, MN) in the hippocampus, CSF, and plasma, as well as TrkA (R&D Systems), TrkB (R&D Systems) and p75<sup>NTR</sup> (EIAAB Inc.) levels in the hippocampus of WT and APP/PS1 mice. The relative optical intensity of each well was read by a microplate reader (BioRad 480; BioRad, Hercules, CA).

### Statistical Analysis

Statistical significance was assessed by one-way analysis of variance (ANOVA) followed by Sheffé's test.  $P < 0.05$  was taken as statistically significant.

## RESULTS

### BDNF mRNA 3'UTR Was a Target of miR-206

In APP/PS1 mice at E14, the miR-206 level in the hippocampus was about 6-fold that in WT mice (Fig. 1A). As previous studies showed that miRNAs can be secreted into the CSF and plasma<sup>[2]</sup>, we also assessed their miR-206 levels, and found that both were upregulated in APP/PS1 mice compared with the WT mice at E14 (Fig. 1A).

The 3'UTR of human BDNF mRNA contains 3 complementary sequences for miR-206 (Fig. 1B). In SH-Sy5y cells, luciferase reporter assays were performed

in which the expression of firefly was regulated by the BDNF mRNA 3'UTR region complementary to miR-206, and *Renilla* was an internal control for transfection efficiency. We found that miR-206 induced a dose-dependent inhibition of luciferase activity, whereas mutant miR-206 and scrambled control miRNA had no such effect (Fig. 1C, left panel). The mimic of miR-206 markedly inhibited the luciferase activity, while the inhibitor of miR-206 increased it (Fig. 1C, left panel). In SH-Sy5y cells, the EGFP reporter assay confirmed the inhibitory effect of miR-206 on the BDNF mRNA 3'UTR (Fig. 1C, right panel).

To determine the specificity of miR-206 targeting BDNF mRNA, we tested other miRNAs with proposed roles in AD<sup>[3]</sup> against luciferase reporter activity regulated by the BDNF mRNA 3'UTR. Only miR-206 effectively inhibited luciferase activity (Fig. 1D). We then mutated the BDNF mRNA 3'UTR complementary sequence and performed a luciferase assay with either scrambled control miRNA or miR-206. Our results showed that miR-206 only suppressed the luciferase activity with the WT BDNF mRNA 3'UTR, but not with the mutant 3'UTR (Fig. 2A), suggesting the specificity of the interaction between miR-206 and the BDNF mRNA 3'UTR. To further validate that the BDNF

mRNA 3'UTR was one of the targets for miR-206, we made mutant a BDNF mRNA 3'UTR with two repeats of the putative complementary binding domain (BD) sequence (2BD) and three repeats of the BD sequence (3BD) for each putative binding site. The luciferase reporter system showed that miR-206 did not suppress the luciferase activity regulated by the unrelated MAP2 mRNA 3'UTR (Fig. 2B). With the BDNF mRNA 3'UTR, luciferase activity was greatly reduced in a BD dose-dependent manner (Fig. 2B). A time-course study showed that miR-206 began to inhibit luciferase activity from 12 h of treatment (Fig. 2C). Western blotting further confirmed that miR-206 decreased the BDNF level (Fig. 2D). miR-206 downregulated the levels of both BDNF in cellular extracts and secreted BDNF, whereas the miR-206 inhibitor increased both cellular and secreted BDNF (Fig. 2D).

**BDNF Was Decreased in AD Transgenic Mice and Protected Against Cell Death**

ELISA showed that the BDNF level in hippocampal tissue was decreased in APP/PS1 mice compared with WT mice (Fig. 3A) at the E14 and newborn (P0) stages. The levels of BDNF in the CSF and plasma were also significantly lower






Fig. 1. miR-206 regulated the BDNF mRNA 3'UTR. A: miR-206 was increased in hippocampal tissue, CSF, and plasma of APP/PS1 mice compared with WT mice at E14. B: Sequence alignment of human miR-206 and the BDNF mRNA 3'UTR region. C: Dose responses of miR-206 in the luciferase reporter assay (left) and EGFP reporter assay (right) in SH-Sy5y cells. D: Other microRNAs were tested against luciferase activity driven by the BDNF mRNA 3'UTR. Only miR-206 specifically decreased the luciferase activity.



**Fig. 2.** miR-206 decreased BDNF expression. **A:** Left panel, miR-206 reduced the luciferase activity with the WT BDNF mRNA 3'UTR, but not with the mutant BDNF mRNA 3'UTR. Right panel, miR-206 reduced the EGFP reporter activity with the WT BDNF mRNA 3'UTR, but not with the mutant BDNF mRNA 3'UTR. **B:** miR-206 did not alter the expression with an unrelated MAP2 mRNA 3'UTR. With BDNF mRNA 3'UTRs constructed with 2 or 3 duplicates of the putative binding domain (2BD, 3BD) of each binding site, miR-206 decreased the luciferase activity remarkably in a dose-dependent manner. **C:** Time-course of miR-206 inhibition of the BDNF mRNA 3'UTR. **D:** Western blots of BDNF showed that a mimic of miR-206 (lane 2) reduced, whereas an inhibitor of miR-206 (lane 3) increased the BDNF level, including BDNF from cell extracts and secreted BDNF (s-BDNF) from the medium. Mutant miR-206 (lane 4) did not alter BDNF levels. Data are mean  $\pm$  SE ( $n = 3$  for each group). **\*\*** $P < 0.01$  compared with control.



**Fig. 3.** BDNF was downregulated in APP/PS1 mice. **A:** At E14 and P0, BDNF decreased in the hippocampal tissue, CSF, and plasma in APP/PS1 mice compared with WT mice. **B:** At E14, TrkA and TrkB did not change significantly in APP/PS1 mouse hippocampal tissue. p75<sup>NTR</sup> decreased in APP/PS1 compared with WT mice.


in APP/PS1 mice than in WT mice at both stages (Fig. 3A). We also assessed the levels of TrkA, TrkB, and p75<sup>NTR</sup>, receptors for BDNF<sup>[18]</sup>, in hippocampal tissues at E14 and P0, and found no significant changes of TrkA and TrkB levels at either stage (Fig. 3B). The p75<sup>NTR</sup> level was lower in the APP/PS1 than in the WT mouse tissue (Fig. 3B).

As neuronal loss has been demonstrated in AD pathology<sup>[1]</sup>, we then assessed the vulnerability of cultured WT and APP/PS1 neurons to various insults. Our data showed that extracellular A $\beta$ <sub>1-42</sub><sup>[27, 29-32]</sup>, serum deprivation<sup>[31, 33]</sup>, staurosporine<sup>[31, 33]</sup>, Etop<sup>[31]</sup> and glutamate<sup>[34]</sup> induced more

severe cell death in cultured APP/PS1 neurons than in WT neurons (Fig. 4). Exogenous administration of BDNF at 1  $\mu$ mol/L<sup>[35, 36]</sup> decreased the vulnerability of APP/PS1 neurons to all the above insults (Fig. 4), suggesting that BDNF plays an important role in neuronal vulnerability and viability/death.

## DISCUSSION

In the present study, we found that miR-206 was upregulated in transgenic APP/PS1 mice. A similar increase



**Fig. 4. BDNF was protective against cell death.** A: Representative images of cultured WT and APP/PS1 neurons treated with BDNF or vehicle in the presence of 10  $\mu$ mol/L extracellular A $\beta$ <sub>1-42</sub>. Blue, Hoechst staining indicating nuclei; green, TUNEL staining indicating apoptotic cells. Scale bar, 50  $\mu$ m. B: In cultured WT and APP/PS1 neurons, toxicity was induced by extracellular A $\beta$ <sub>1-42</sub>, serum deprivation, STS, Etop, and glutamate. The neurons were treated with BDNF at 1  $\mu$ mol/L in the culture medium. Cell death was measured 24 h after treatment. Data are mean  $\pm$  SE ( $n = 3$  for each group). \*\* $P < 0.01$  compared with APP/PS1 neurons.

of miR-206 has been reported in Tg2576 AD transgenic mice and in the temporal cortex of human AD brains<sup>[37]</sup>. Furthermore, miR-206 targeted the 3'UTR of BDNF mRNA and decreased the BDNF level in AD transgenic mouse neurons, which is also consistent with the report that miR-206 targets BDNF transcripts<sup>[37]</sup>. Further, BDNF was protective against cell death induced by extracellular A $\beta$ <sub>1-42</sub>, STS, Etop, serum deprivation, and glutamate. The mechanism of BDNF protection is yet to be fully understood. It has been reported that A $\beta$ <sub>1-42</sub> inhibits the BDNF-induced expression of Arc, an immediate-early gene responding to the BDNF signal, in cultured neurons<sup>[38-40]</sup>. Arc is associated with synaptic plasticity and the induction of long-term potentiation<sup>[41]</sup> and may be linked to AD pathology. A reduced level of BDNF in AD has also been associated with increased pro-inflammatory activity<sup>[42-44]</sup>, alterations of oxidative stress and mitochondrial dysfunction<sup>[45]</sup>, downregulation of hippocampal neurogenesis<sup>[46, 47]</sup>, and GSK3 $\beta$  hyperactivity<sup>[48-50]</sup>. Further studies are needed to discover the mechanisms of miR-206 regulation in AD animal models and BDNF protection. Finally, AD has been considered to be an aging-related disorder. Our data showed that developmental defects, including microRNA regulation and BDNF expression and secretion may be involved in AD pathogenesis.

## ACKNOWLEDGEMENTS

This work was supported by a National Natural Science Foundation of China (91132718).

Received date: 2013-08-29; Accepted date: 2013-11-06

## REFERENCES

- [1] Price DL, Sisodia SS, Gandy SE. Amyloid beta amyloidosis in Alzheimer's disease. *Curr Opin Neurol* 1995, 8: 268–274.
- [2] Chan AW, Kocerha J. The path to microRNA therapeutics in psychiatric and neurodegenerative disorders. *Front Genet* 2012, 3: 82.
- [3] Delay C, Mandemakers W, Hebert SS. MicroRNAs in Alzheimer's disease. *Neurobiol Dis* 2012, 46: 285–290.
- [4] Delay C, Hebert SS. MicroRNAs and Alzheimer's disease mouse models: Current insights and future research avenues. *Int J Alzheimers Dis* 2011, 2011: 894938.
- [5] Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. *Science* 2001, 294: 853–858.
- [6] Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, Jongens TA, *et al.* Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. *Nat Neurosci* 2004, 7: 113–117.
- [7] Ashraf SI, McLoon AL, Sclarsic SM, Kunes S. Synaptic protein synthesis associated with memory is regulated by the RISC pathway in *Drosophila*. *Cell* 2006, 124: 191–205.
- [8] Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, *et al.* LNA-mediated microRNA silencing in non-human primates. *Nature* 2008, 452: 896–899.
- [9] Hollander JA, Im HI, Amelio AL, Kocerha J, Bali P, Lu Q, *et al.* Striatal microRNA controls cocaine intake through CREB signalling. *Nature* 2010, 466: 197–202.
- [10] Peters L, Meister G. Argonaute proteins: mediators of RNA silencing. *Mol Cell* 2007, 26: 611–623.
- [11] Eulalio A, Huntzinger E, Nishihara T, Rehwinkel J, Fauser M, Izaurralde E. Deadenylation is a widespread effect of miRNA regulation. *RNA* 2009, 15: 21–32.
- [12] Meister G. miRNAs get an early start on translational silencing. *Cell* 2007, 131: 25–28.
- [13] Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. *Nature* 2008, 455: 64–71.
- [14] Selbach M, Schwanhauser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. *Nature* 2008, 455: 58–63.
- [15] Diniz BS, Teixeira AL. Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. *Neuromolecular Med* 2011, 13: 217–222.
- [16] Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. *Brain Res Rev* 2008, 59: 201–220.
- [17] Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. *Nat Rev Neurosci* 2003, 4: 299–309.
- [18] Reichardt LF. Neurotrophin-regulated signalling pathways. *Philos Trans R Soc Lond B Biol Sci* 2006, 361: 1545–1564.
- [19] Arancibia S, Silhol M, Mouliere F, Meffre J, Hollinger I, Maurice T, *et al.* Protective effect of BDNF against beta-amyloid induced neurotoxicity *in vitro* and *in vivo* in rats. *Neurobiol Dis* 2008, 31: 316–326.
- [20] Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, *et al.* Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. *Nat Med* 2009, 15: 331–337.
- [21] Poon WW, Blurton-Jones M, Tu CH, Feinberg LM, Chabrier MA, Harris JW, *et al.* beta-Amyloid impairs axonal BDNF retrograde trafficking. *Neurobiol Aging* 2011, 32: 821–833.
- [22] Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM, *et al.* Decreased brain-derived neurotrophic

- factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. *J Neurosci* 2009, 29: 9321–9329.
- [23] Kunugi H, Ueki A, Otsuka M, Isse K, Hirasawa H, Kato N, *et al.* A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease. *Mol Psychiatry* 2001, 6: 83–86.
- [24] Tsai SJ, Hong CJ, Liu HC, Liu TY, Hsu LE, Lin CH. Association analysis of brain-derived neurotrophic factor Val66Met polymorphisms with Alzheimer's disease and age of onset. *Neuropsychobiology* 2004, 49: 10–12.
- [25] Tsai SJ, Hong CJ, Liu HC, Liu TY, Liou YJ. The brain-derived neurotrophic factor gene as a possible susceptibility candidate for Alzheimer's disease in a chinese population. *Dement Geriatr Cogn Disord* 2006, 21: 139–143.
- [26] Olin D, MacMurray J, Comings DE. Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism. *Neurosci Lett* 2005, 381: 275–278.
- [27] Cui J, Wang Y, Dong Q, Wu S, Xiao X, Hu J, *et al.* Morphine protects against intracellular amyloid toxicity by inducing estradiol release and upregulation of Hsp70. *J Neurosci* 2011, 31: 16227–16240.
- [28] Wang Y, Cui J, Sun X, Zhang Y. Tunneling-nanotube development in astrocytes depends on p53 activation. *Cell Death Differ* 2011, 18: 732–742.
- [29] Zhang Y, Champagne N, Beitel LK, Goodyer CG, Trifiro M, LeBlanc A. Estrogen and androgen protection of human neurons against intracellular amyloid beta1-42 toxicity through heat shock protein 70. *J Neurosci* 2004, 24: 5315–5321.
- [30] Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. *J Cell Biol* 2002, 156: 519–529.
- [31] Cui J, Chen Q, Yue X, Jiang X, Gao GF, Yu LC, *et al.* Galanin protects against intracellular amyloid toxicity in human primary neurons. *J Alzheimers Dis* 2010, 19: 529–544.
- [32] Zhang Y, Hong Y, Bounhar Y, Blacker M, Roucou X, Tounekti O, *et al.* p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. *J Neurosci* 2003, 23: 7385–7394.
- [33] Zhang Y, Goodyer C, LeBlanc A. Selective and protracted apoptosis in human primary neurons microinjected with active caspase-3, -6, -7, and -8. *J Neurosci* 2000, 20: 8384–8389.
- [34] Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic–ischemic brain damage. *Ann Neurol* 1986, 19: 105–111.
- [35] Ji Y, Lu Y, Yang F, Shen W, Tang TT, Feng L, *et al.* Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. *Nat Neurosci* 2010, 13: 302–309.
- [36] Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, *et al.* Blood BDNF concentrations reflect brain-tissue BDNF levels across species. *Int J Neuropsychopharmacol* 2011, 14: 347–353.
- [37] Lee ST, Chu K, Jung KH, Kim JH, Huh JY, Yoon H, *et al.* miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. *Ann Neurol* 2012, 72: 269–277.
- [38] Chen TJ, Wang DC, Chen SS. Amyloid-beta interrupts the PI3K-Akt-mTOR signaling pathway that could be involved in brain-derived neurotrophic factor-induced Arc expression in rat cortical neurons. *J Neurosci Res* 2009, 87: 2297–2307.
- [39] Echeverria V, Berman DE, Arancio O. Oligomers of beta-amyloid peptide inhibit BDNF-induced arc expression in cultured cortical Neurons. *Curr Alzheimer Res* 2007, 4: 518–521.
- [40] Wang DC, Chen SS, Lee YC, Chen TJ. Amyloid-beta at sublethal level impairs BDNF-induced arc expression in cortical neurons. *Neurosci Lett* 2006, 398: 78–82.
- [41] Bramham CR, Worley PF, Moore MJ, Guzowski JF. The immediate early gene arc/arg3.1: regulation, mechanisms, and function. *J Neurosci* 2008, 28: 11760–11767.
- [42] Forlenza OV, Diniz BS, Talib LL, Mendonca VA, Ojopi EB, Gattaz WF, *et al.* Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment. *Dement Geriatr Cogn Disord* 2009, 28: 507–512.
- [43] Diniz BS, Teixeira AL, Ojopi EB, Talib LL, Mendonca VA, Gattaz WF, *et al.* Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease. *J Alzheimers Dis* 2010, 22: 1305–1311.
- [44] Mrak RE. Neuropathology and the neuroinflammation idea. *J Alzheimers Dis* 2009, 18: 473–481.
- [45] Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis. *J Alzheimers Dis* 2010, 20 Suppl 2: S265–279.
- [46] Shruster A, Melamed E, Offen D. Neurogenesis in the aged and neurodegenerative brain. *Apoptosis* 2010, 15: 1415–1421.
- [47] Chen Q, Nakajima A, Choi SH, Xiong X, Sisodia SS, Tang YP. Adult neurogenesis is functionally associated with AD-like neurodegeneration. *Neurobiol Dis* 2008, 29: 316–326.
- [48] Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnesic mild cognitive impairment: randomised controlled trial. *Br J Psychiatry* 2011, 198: 351–356.
- [49] Forlenza OV, Torres CA, Talib LL, de Paula VJ, Joaquim HP, Diniz BS, *et al.* Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. *J Psychiatr Res* 2011, 45: 220–224.
- [50] Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. *J Neurochem* 2008, 104: 1433–1439.